Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 6/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168299 | 1.00 | ACE (0.36) | ACERENBMP1DPP4F2 | |
| SCHEMBL21168320 | 1.00 | ACE (0.36) | ACERENBMP1DPP4F2 | |
| SCHEMBL31490055 | 0.99 | ACE (0.36) | ACERENBMP1DPP4F2 | |
| SCHEMBL21168356 | 0.97 | ACE (0.36) | ACERENBMP1DPP4F2 | |
| SCHEMBL21168275 | 0.97 | ACE (0.36) | ACERENBMP1DPP4F2 | |
| SCHEMBL21168498 | 0.96 | ACE (0.34) | ACERENDPP4F2FABP4 | |
| SCHEMBL21168293 | 0.95 | BMP1 (0.31) | ACERENBMP1DPP4FABP4 | |
| SCHEMBL21168294 | 0.95 | BMP1 (0.31) | ACERENBMP1DPP4FABP4 | |
| SCHEMBL21168290 | 0.95 | FABP4 (0.32) | RENBMP1DPP4FABP4FABP5 | |
| SCHEMBL21168289 | 0.95 | FABP4 (0.32) | RENBMP1DPP4FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029162-A | Pharmaceutically acceptable salts of CD47-SIRP alpha pathway inhibitors | 奥瑞基尼肿瘤有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025083628-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF A CD47-SIRP ALPHA PATHWAY INHIBITOR | AURIGENE ONCOLOGY LIMITED (IN) | 2025-04-24 | — | — | WO | disclosed |